Saw palmetto: what the large trials actually found
The best-selling prostate ingredient in America failed the two biggest US trials ever run on it — including one that tripled the dose. Here is what happened, and why the debate continues anyway.
The short answer
- Two large NIH-funded US trials — STEP in 2006 and CAMUS in 2011 — found saw palmetto no better than placebo for urinary symptoms.
- CAMUS escalated the dose to three times the standard 320 mg and still found nothing. That closes off the usual "you weren’t taking enough" explanation.
- The Cochrane review reached the same conclusion after pooling the evidence.
- Earlier positive results came from smaller, shorter, often industry-funded studies — a pattern that repeats across nutrition research.
- It remains the best-selling prostate ingredient in the United States. Sales and evidence are not the same thing.
If you own a prostate supplement, there is a good chance saw palmetto is the first thing on the label. It has been the category's anchor ingredient for three decades, it appears in nearly every formula on the shelf, and its name recognition among American men over 50 is close to universal.
It also has the weakest trial record of the five ingredients we cover — and the gap between those two facts is worth understanding, because it tells you something about how this entire category works.
What the trials did
Both studies were funded by the National Institutes of Health rather than by anyone selling the product. That matters: it removes the most obvious reason for a study to find what its sponsor hoped it would find.
- CAMUS (2011) 369 participants
No better than placebo — NIH-funded, 72 weeks, doses escalated to 960 mg/day
- STEP (2006) 225 participants
No better than placebo — NIH-funded, one year, 320 mg/day
Neither trial found a difference from placebo on standardized urinary symptom scores. Bar length reflects the number of participants.
STEP, published in the New England Journal of Medicine in 2006, followed 225 men with moderate-to-severe symptoms for a full year on the standard 320 mg daily dose. Symptom scores improved in both groups — as they reliably do in trials of this kind, because urinary symptoms fluctuate and people who enroll in studies tend to change other habits too. The improvement in the saw palmetto group was not meaningfully larger than in the placebo group.
CAMUS, published in JAMA in 2011, was designed to answer the objection that followed. If 320 mg wasn't enough, the researchers reasoned, let's find out. They enrolled 369 men and escalated the dose in stages up to 960 mg per day over 72 weeks. Still nothing. The result held at every dose level.
Why the early studies looked so good
Saw palmetto did not build its reputation on nothing. Through the 1990s a series of trials and a widely cited 1998 meta-analysis reported real improvements, and that body of work is what put the ingredient into every pharmacy in the country.
The trials in it were small, ran for weeks rather than a year, frequently had no proper blinding, and were often funded by manufacturers. Each of those weaknesses pushes results in the same direction — toward a positive finding. When researchers built studies that removed them, the effect went with them.
This is not a scandal so much as a familiar sequence. It has played out with several supplement ingredients, and it is the reason we weight a 369-person NIH trial above a dozen 40-person industry ones no matter how the arithmetic of "twelve studies versus one" might look.
The strongest counter-argument
Defenders of the ingredient make one point that deserves to be taken seriously: not all saw palmetto is the same substance.
The berry can be extracted with supercritical CO2, with ethanol, or with hexane, and each method pulls a different mix of fatty acids and sterols into the final oil. Most European research used one specific hexane-extracted preparation, and those trials generally read more favorably than the American ones. If the extraction method genuinely determines the activity, then the US trials tested a different thing and their null result says less than it appears to.
Whether that holds up is unresolved. The European trials were also predominantly funded by the company making that extract, which brings back the problem the NIH funding was meant to solve.
What we can say without hedging: it is not an argument for the generic bottle in front of you. That product almost certainly does not specify its extraction method, and if it doesn't, you have no way to know which version you're buying.
What this means when you're choosing a formula
Saw palmetto being the headline ingredient is not a reason to buy a product. Turn the bottle over and look at what else is in it, and at what dose. Of the common ingredients, beta-sitosterol has the more consistent trial support for urinary symptoms — and it's usually the one present in a token amount while saw palmetto takes the top billing.
Beta-sitosterol vs saw palmetto: how the evidence compares →
Or read the full ingredient breakdown →
And the safety picture: side effects and drug interactions →
Or pumpkin seed oil, which is often sold combined with it →
Common questions
So does saw palmetto do nothing at all?
The honest answer is that the largest and best-controlled trials could not detect a benefit over placebo, and that is the strongest evidence available. It does not prove the extract is inert in every preparation and every population. It does mean that anyone selling it to you is selling something that failed its two best tests.
Why did older studies look positive then?
The early meta-analyses pooled small, short trials, many of them industry-funded and several without proper blinding. When researchers ran larger trials with tighter methods, the effect disappeared. That pattern — promising small studies, null large ones — is common enough in nutrition research to be almost expected.
Is the European extract different?
This is the strongest argument the ingredient has. Extraction method changes what ends up in the capsule, and some European trials of one specific hexane-extracted preparation reported better results than the US trials of generic supercritical CO2 extracts. Whether that difference is real or reflects who funded the studies is still argued. It is not an argument that a generic bottle will work.
Is it safe?
It is generally well tolerated. The most common complaints are mild digestive upset and headache, and trial dropout rates for side effects were similar to placebo. There are isolated case reports of liver injury and of bleeding, which is why it belongs on the list you show your pharmacist rather than one you keep to yourself.
Continue reading
Sources
- Bent S, et al. Saw palmetto for benign prostatic hyperplasia. New England Journal of Medicine, 2006.
- Barry MJ, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms (CAMUS). JAMA, 2011.
- Tacklind J, et al. Serenoa repens for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews.
- National Center for Complementary and Integrative Health. Saw Palmetto.